fda compounding glp-1 enforcement news november 2025 Federal watchdog looks at compounded oversight Drugmakers battle pharmacies over compounded

Clinical Efficacy The primary endpoint efficacy indicator was HbA1c (6 points)

Private Insurance Coverage is highly variable: Most plans cover for diabetes (Ozempic, Mounjaro) Obesity coverage (Wegovy, Zepbound) is inconsistent Many require BMI 30+ or BMI 27+ with comorbidities Prior authorization almost always required Some plans increased BMI thresholds to 32 or 35 in 2024-2025 Tip: If denied, appeals often succeed with documentation of metabolic dysfunction (elevated fasting glucose, insulin resistance, lipid abnormalities)

A bag that just feels cool for a little while isnt enough

Q: Is this suitable for long-term use